WallStreetZenWallStreetZen

NASDAQ: VRCA
Verrica Pharmaceuticals Inc Stock

$5.92+0.27 (+4.78%)
Updated Mar 28, 2024
VRCA Price
$5.92
Fair Value Price
$0.41
Market Cap
$251.12M
52 Week Low
$2.86
52 Week High
$7.76
P/E
-4x
P/B
12.71x
P/S
64.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.12M
Earnings
-$67.00M
Gross Margin
85.4%
Operating Margin
-1,230.15%
Profit Margin
-1,307.5%
Debt to Equity
3.13
Operating Cash Flow
-$39M
Beta
1.55
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VRCA Overview

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VRCA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VRCA ($5.92) is overvalued by 1,330.59% relative to our estimate of its Fair Value price of $0.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRCA ($5.92) is not significantly undervalued (1,330.59%) relative to our estimate of its Fair Value price of $0.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRCA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRCA due diligence checks available for Premium users.

Be the first to know about important VRCA news, forecast changes, insider trades & much more!

VRCA News

Valuation

VRCA fair value

Fair Value of VRCA stock based on Discounted Cash Flow (DCF)
Price
$5.92
Fair Value
$0.41
Overvalued by
1,330.59%
VRCA ($5.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRCA ($5.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRCA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VRCA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4x
Industry
14.26x
Market
44.51x

VRCA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
12.71x
Industry
6.21x
VRCA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VRCA's financial health

Profit margin

Revenue
$2.0M
Net Income
-$24.6M
Profit Margin
-1,238.1%
VRCA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VRCA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$81.6M
Liabilities
$61.8M
Debt to equity
3.13
VRCA's short-term assets ($77.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRCA's short-term assets ($77.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRCA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VRCA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.5M
Investing
-$227.0k
Financing
-$27.0k
VRCA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VRCA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VRCA$251.12M+4.78%-4.00x12.71x
GRTS$252.03M-8.21%-2.14x4.86x
ELEV$249.58M+2.40%-3.83x4.55x
QURE$248.76M-3.88%-0.80x1.20x
PYXS$247.65M+1.43%-2.30x1.97x

Verrica Pharmaceuticals Stock FAQ

What is Verrica Pharmaceuticals's quote symbol?

(NASDAQ: VRCA) Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol VRCA. Verrica Pharmaceuticals stock quotes can also be displayed as NASDAQ: VRCA.

If you're new to stock investing, here's how to buy Verrica Pharmaceuticals stock.

What is the 52 week high and low for Verrica Pharmaceuticals (NASDAQ: VRCA)?

(NASDAQ: VRCA) Verrica Pharmaceuticals's 52-week high was $7.76, and its 52-week low was $2.86. It is currently -23.66% from its 52-week high and 106.99% from its 52-week low.

How much is Verrica Pharmaceuticals stock worth today?

(NASDAQ: VRCA) Verrica Pharmaceuticals currently has 42,418,553 outstanding shares. With Verrica Pharmaceuticals stock trading at $5.92 per share, the total value of Verrica Pharmaceuticals stock (market capitalization) is $251.12M.

Verrica Pharmaceuticals stock was originally listed at a price of $17.50 in Jun 15, 2018. If you had invested in Verrica Pharmaceuticals stock at $17.50, your return over the last 5 years would have been -66.17%, for an annualized return of -19.49% (not including any dividends or dividend reinvestments).

How much is Verrica Pharmaceuticals's stock price per share?

(NASDAQ: VRCA) Verrica Pharmaceuticals stock price per share is $5.92 today (as of Mar 28, 2024).

What is Verrica Pharmaceuticals's Market Cap?

(NASDAQ: VRCA) Verrica Pharmaceuticals's market cap is $251.12M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Verrica Pharmaceuticals's market cap is calculated by multiplying VRCA's current stock price of $5.92 by VRCA's total outstanding shares of 42,418,553.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.